ARTICLE | Company News

Shire evaluating neurology pipeline

August 4, 2017 7:58 PM UTC

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The company expects to complete its analysis by year end.

Shire’s ADHD sales comprised 17% of its product sales this quarter. The franchise revenues fell 3% to $635.4 million in 2Q17, primarily due to generic competition for Adderall XR. Shire also markets amphetamine drugs Elvanse and Vyvanse, as well as adrenergic receptor alpha 2A (ADRA2A) agonist Intuniv, for ADHD. The company plans to launch Mydayis for the indication in 3Q17. FDA approved Mydayis, which consists of 3-component, extended release, single-entity mixed amphetamine salts (MAS), in June (see BioCentury, June 26)...

BCIQ Company Profiles

Shire plc